Hemispheric lesion asymmetry flagged as overlooked tDCS variable in MS

A paper published online 18 October 2026 in Clinical Neurophysiology argues that hemispheric lesion asymmetry — the imbalance of demyelinating lesions between the two cerebral hemispheres — is an overlooked variable when clinicians target transcranial direct current stimulation (tDCS) in multiple sclerosis. Author Hussein Youssef makes the case that the field's conventional, symmetric approach to electrode placement may not fit a disease whose pathology is frequently lateralized.

The argument lands at a moment when tDCS protocols in MS are proliferating across trials and rehabilitation units, most of them using standardized montages that treat the two hemispheres as interchangeable targets. For readers running neurophysiology labs or monitoring units, the core question is straightforward: should a patient with a heavy left-hemisphere lesion load receive the same montage as one with balanced or right-dominant pathology? Youssef's answer, as framed in the publication, is no.

What is the variable at issue?

Lesion asymmetry in MS is not a marginal feature. Conventional MRI reporting already documents inter-hemispheric differences in lesion burden, yet tDCS targeting practice has largely ignored this dimension, defaulting to midline or symmetric electrode placements validated in healthy cohorts or mixed neurological populations. The paper positions this mismatch as a methodological blind spot.

The practical implications for the reading room and the stimulation suite run in parallel:

• Montage selection may need to account for individual lesion distribution rather than diagnosis alone.
• Trial stratification by lesion asymmetry could explain part of the response variability reported across MS stimulation studies.
• Sham-controlled designs that randomize montage without documenting hemispheric burden risk confounding their primary endpoints.

How should practitioners read this?

The publication is an analytical contribution, not a new device clearance. No FDA-cleared tDCS system specific to MS lesion-asymmetry targeting exists; tDCS itself remains an investigational application in this population outside approved indications. Readers should treat the paper as a hypothesis-generating argument about targeting methodology, grounded in the clinical neurophysiology literature rather than in a new interventional dataset.

For neurophysiologists who already report structural imaging alongside EEG and evoked-potential work, the paper suggests a workflow change with low cost: quantify or at least note hemispheric lesion predominance when a stimulation referral or research protocol crosses the desk. That single documentation step, the argument implies, could later separate responders from non-responders in retrospective review.

Why does the timing matter?

The paper appears as tDCS research in MS accelerates worldwide, with cognitive and fatigue endpoints dominating trial registries. A targeting variable that is cheap to assess — lesion laterality is visible on any routine MRI report — carries obvious appeal for labs seeking to personalize protocols without new hardware.

The editorial weight of the venue matters here. Clinical Neurophysiology, the journal of the International Federation of Clinical Neurophysiology, publishes methodological standards that labs frequently adopt as reference practice, so a targeting argument in its pages will likely reach protocol committees and trial design groups rather than remaining a theoretical exchange.

What changes next?

Whether lesion-asymmetry-guided montages outperform conventional placements will require prospective, stratified trials with pre-registered laterality documentation — a design decision the paper's appearance may now push into upcoming MS stimulation protocols.